Stability-Indicating RP-LC Method for the Determination of Vildagliptin and Mass Spectrometry Detection for a Main Degradation Product

被引:32
作者
Barden, Amanda Thomas [1 ]
Salamon, Barbara [1 ]
Sherman Schapoval, Elfrides Eva [1 ]
Steppe, Martin [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Postgrad Program Pharmaceut Sci, Porto Alegre, RS, Brazil
关键词
Degradation - Drug dosage - Drug products - Liquid chromatography - Quality control;
D O I
10.1093/chromsci/bms024
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, precise and stability-indicating reversed-phase liquid chromatography method was developed and validated for the determination of vildagliptin (VLG) in pharmaceutical dosage form. The chromatographic separation was obtained within 6 min and was linear in the range of 20-80 mu g/mL (r(2) = 0.9999). Limit of detection and limit of quantitation were 0.63 and 2.82 mu g/mL, respectively. The method was validated in accordance with International Conference on Harmonization acceptance criteria for specificity, linearity, precision, accuracy, robustness and system suitability. Stress studies were carried out and no interference of the degradation products was observed. The excipients did not interfere in the determination of VLG. Furthermore, the main degradation product obtained from the stress studies (thermal, oxidative and alkaline hydrolysis) was evaluated for mass spectrometry and its molecular structure was predicted. The proposed method was successfully applied for the quantitative analysis of VLG in tablet dosage form, which will help to improve quality control and contribute to stability studies of pharmaceutical tablets containing this drug.
引用
收藏
页码:426 / 432
页数:7
相关论文
共 7 条
[1]  
[Anonymous], 2005, TEXT METHODOLOGY
[2]   Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin [J].
Bolli, G. ;
Dotta, F. ;
Colin, L. ;
Minic, B. ;
Goodman, M. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :589-595
[3]  
Ermer J, 2005, METHOD VALIDATION IN PHARMACEUTICAL ANALYSIS: A GUIDE TO BEST PRACTICE, P1
[4]  
Food and Drug Administration, 2003, LAB OP APPL PROGR, V3
[5]  
ICH, 2003, Topic Q. A (R2) Stability Testing of New Drug Substances and Products Step 5 NOTE FOR GUIDANCE ON STABILITY TESTING: STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS, P1
[6]   In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma [J].
Jost, Marco M. ;
Lamerz, Jens ;
Tammen, Harald ;
Menzel, Christoph ;
De Meester, Ingrid ;
Lambeir, Anne-Marie ;
Augustyns, Koen ;
Scharpe, Simon ;
Zucht, Hans Dieter ;
Rose, Horst ;
Juergens, Michael ;
Schulz-Knappe, Peter ;
Budde, Petra .
BIOCHEMICAL PHARMACOLOGY, 2009, 77 (02) :228-237